On the 23rd July 2015 Anteo announced their partnership with "Global Life Science company" the $16.7 BILLION company SIGMA ALDRICH
From the article above dated 22nd June 2015 :
"The company has filed a patent for development of a proprietary diagnostic test for blood purification and is developing the product with a “global life science company.” Anteo has partnership arrangements with University of Queensland and Cook Medical Australia to use Nanoglue in the implantable medical device market. A recent investor presentation stated the company’s intention to file a patent “in the near future."
This was the first time I could remember any detail of what the joint project was with the "Global Life Science Company" was - A month later we fund out the GLSC was in fact SIGMA ALDRICH
This below was from ADO Quarterly Report dated 30th January 2015 :
(Before we knew the "Global Life Science Company" was SIGMA ALDRICH)
"Global Life Science Company - has been assessing Mix&Go for a variety of applications over several years. Their technical appraisal has now been satisfactorily completed and it was broader than we initially anticipated. They were impressed with the outcomes to the extent that they have indicated a desire to utilize Mix&Go as a “platform technology” for incorporation into a number of their proprietary products. Further, a welcome additional outcome is they want to include Anteo’s AMG Mix&Go products into their highly respected catalogue"
So while there has been focus to date on the initial launch of AMG products into the SIGMA catalogue the main game is by the looks - SIGMA using Anteo's technology as a Platform Technology in SIGMA's own proprietary products
What I found interesting was the focus of the content released in the Proactive Investor story released on the 1st October 2015 :
"The field of bioseparations encompasses methods for the purification of biological products as is necessary in medical research programs. This helps drive a broader, lab-based medical testing industry estimated to value $62.6 billion by 2017."
"Anteo’s Mix&Go Nanoglue products employ fine-scale nanotechnology in bioseparations processes including blood bank sampling and testing, protein purification and drug manufacturing.
On this front, the company advises that it is undertaking a collaborative project with a global life science group that is extending an existing Anteo product to deliver a proprietary bioseparations product."
The above focus to me with SIGMA has gone totally under the radar by the market IMO
This is the continuation of the business plan that began when money was raised in late 2013
Sounds like some more big news from SIGMA and Anteo could be on the cards?
Some may not have seen this video below :
These opportunities are very significant and IMO could see large Joint Ventures and new potential subsidiary companies to exploit the value of Anteo's technology in these fields
Big few weeks ahead
ADO Price at posting:
10.0¢ Sentiment: Buy Disclosure: Held
